We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Baxalta Incorporated | NYSE:BXLT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 46.02 | 0 | 01:00:00 |
From May 2019 to May 2024
By Tess Stynes
Shire PLC said Tuesday that it has offered to acquire Baxalta Inc. in a stock deal valued at roughly $30.6 billion, in a combination what would create a leader in treatments for rare diseases.
Under the proposed deal, Baxalta holders would receive 0.1687 Shire American depositary share for each Baxalta share held, implying a value of $45.23 per Baxalta share and a premium of 36% based on Monday's closing prices.
Baxalta shares rose 27% to $42.10 in recent premarket trading, while Shire's ADRs were halted.
A Baxalta spokesman wasn't immediately available to comment.
The offer comes just more than a month after Baxalta, which sells treatments for rare bleeding disorders and immune deficiencies, completed its spinoff from Baxter International Inc. Baxter remains Baxalta's biggest shareholder, with a stake of about 24%, according to FactSet.
In 2014, Baxalta had net sales of $6 billion and net income from continuing operations of $1.2 billion.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Baxalta Incorporated Chart |
1 Month Baxalta Incorporated Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
